Cadrenal Therapeutics Q1 net loss $2.5M; details Phase 3 plan for CAD-1005 in HIT

Cadrenal Therapeutics, Inc.

2026-Q1 EPS reported -$1.04

Net loss $2.5M in Q1 2026 vs $3.8M in Q1 2025; operating expenses $2.5M vs $3.9M.
Cash $2.3M at March 31; subsequent $2.5M financing completed April 1, 2026.
Received FDA EOP2 meeting minutes; plans randomized, blinded, placebo-controlled Phase 3 trial in ~120 HIT patients.
Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 added to standard anticoagulant therapy.
CAD-1005 is first-in-class 12-LOX inhibitor; holds FDA Orphan Drug and Fast Track designations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cadrenal Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $2.5 million.

Period: the quarter ended March 31, 2026
Net income: $2.5 million
Result: reported results

Exact text from the filing

Cadrenal reported a net loss of $2.5 million for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-053075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.